Gene Expression Profile and Acute Gene Expression Response to Sclerostin Inhibition in Osteogenesis Imperfecta Bone

Sclerostin antibody (SclAb) therapy has been suggested as a novel therapeutic approach toward addressing the fragility phenotypic of osteogenesis imperfecta (OI). Observations of cellular and transcriptional responses to SclAb in OI have been limited to mouse models of the disorder, leaving a paucit...

Descripción completa

Detalles Bibliográficos
Autores principales: Surowiec, Rachel K, Battle, Lauren F, Schlecht, Stephen H, Wojtys, Edward M, Caird, Michelle S, Kozloff, Kenneth M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422710/
https://www.ncbi.nlm.nih.gov/pubmed/32803109
http://dx.doi.org/10.1002/jbm4.10377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422710/
https://www.ncbi.nlm.nih.gov/pubmed/32803109
http://dx.doi.org/10.1002/jbm4.10377

Ejemplares similares